MedDataX Logo

Preliminary Efficacy and Safety Study of ST101 in Alzheimer's Disease

NCT ID: NCT00842673

Last Updated: 2012-06-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

168 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the ability of ST101 to improve memory in people with Alzheimer's disease. This study also will examine the safety and tolerability of the drug. This study is evaluating 3 different dose levels of ST101 and placebo. Patients will have a 1 in 4 chance of getting placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816

Alzheimer's Disease
COMPLETED PHASE2

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059

Alzheimer's Disease
COMPLETED PHASE2

Neurostimulation for Cognitive Enhancement in Alzheimer's Disease

NCT04404153

Alzheimer Disease Dementia
ACTIVE_NOT_RECRUITING NA

Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease

NCT00257673

Alzheimer's Disease
COMPLETED PHASE2

A Study of CST-2032 and CST-107 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's or Alzheimer's Disease

NCT05104463

Mild Cognitive Impairment Dementia
COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's disease (AD) is a progressive and fatal neurological illness. It produces changes in the brain that include loss of cells and accumulation of abnormal protein deposits. Initial symptoms are cognitive, with deficiencies in short-term memory the most common symptom. As the disease progresses so does the severity of cognitive deficiency. Loss of speech and immobility occur in the terminal stages There is no cure for AD and no marketed treatment that modifies the underlying disease process. Available therapies improve some symptoms of AD by increasing brain concentrations of molecules involved in cognition. ST101 differs from marketed therapies in that it has demonstrated two actions in animal research testing. It improves cognition and it also reduces the accumulation of abnormal protein deposits in the brain. These two properties suggest that ST101 may be a promising agent for the treatment of AD. This study is designed as a preliminary dose exploration/proof-of-concept investigation of the ability of ST101 to improve cognition during 12 weeks of administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

30 mg ST101

Group Type EXPERIMENTAL

ST101

Intervention Type DRUG

30 mg; administered once/day

2

90 mg ST101

Group Type EXPERIMENTAL

ST101

Intervention Type DRUG

90 mg; administered once/day

3

180 mg ST101

Group Type EXPERIMENTAL

ST101

Intervention Type DRUG

180 mg; administered once/day

4

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

placebo to match ST101 tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ST101

30 mg; administered once/day

Intervention Type DRUG

ST101

90 mg; administered once/day

Intervention Type DRUG

ST101

180 mg; administered once/day

Intervention Type DRUG

Placebo

placebo to match ST101 tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic evidence of mild to moderate Alzheimer's disease.
* CT or MRI results within the past 12 months that rule out dementia due to non-Alzheimer's etiology.
* A reliable and capable caregiver.

Exclusion Criteria

* Subjects who reside in a skilled nursing facility.
* Subjects with B12 or folate deficiency.
* Subjects with chronic hepatic disease.
* Subjects with a recent history of hematologic/oncologic disorders.
* Subjects who have experienced a myocardial infarction with the past year.
* Dementia caused or complicated by other organic disease
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sonexa Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Costa Mesa, California, United States

Site Status

Redlands, California, United States

Site Status

San Diego, California, United States

Site Status

Walnut Creek, California, United States

Site Status

Deerfield Beach, Florida, United States

Site Status

Delray Beach, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

West Palm Beach, Florida, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Durham, North Carolina, United States

Site Status

Toledo, Ohio, United States

Site Status

Jenkinton, Pennsylvania, United States

Site Status

Wichita Falls, Texas, United States

Site Status

Bennington, Vermont, United States

Site Status

Peterborough, Ontario, Canada

Site Status

Toronto, Ontario, Canada

Site Status

Montreal, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ST101-A001-201

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
NCT03625401 UNKNOWN PHASE2
Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00105547 COMPLETED PHASE3
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
NCT00322153 COMPLETED PHASE3
Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
NCT00722046 COMPLETED PHASE2
A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
NCT06247345 RECRUITING PHASE1
A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease
NCT03462121 COMPLETED PHASE2
Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment
NCT03446001 COMPLETED PHASE3
Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease
NCT00663936 COMPLETED PHASE2
Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease
NCT00708552 COMPLETED PHASE2
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
NCT04685590 ACTIVE_NOT_RECRUITING PHASE2
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease
NCT04488419 COMPLETED PHASE2/PHASE3
Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms
NCT02626572 COMPLETED PHASE2
A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease
NCT02820896 COMPLETED PHASE1
Safety and Efficacy of MT-4666
NCT01764243 COMPLETED PHASE2
A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease
NCT00810147 COMPLETED PHASE2
A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease
NCT00736775 COMPLETED PHASE1
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's Disease
NCT00884507 COMPLETED PHASE2
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease
NCT01689246 COMPLETED PHASE3
A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)
NCT06721156 RECRUITING PHASE2
Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's Disease
NCT00154635 UNKNOWN PHASE2
Study to Evaluate DNL747 in Subjects With Alzheimer's Disease
NCT03757325 COMPLETED PHASE1
Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease
NCT01689233 COMPLETED PHASE3
Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
NCT05225415 COMPLETED PHASE2
Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease
NCT03486938 COMPLETED PHASE2/PHASE3
Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07
NCT02434666 COMPLETED PHASE2